YAPCHomo sapiens (Human)Cancer cell line

Also known as: YPAC (Also in an EFO entry (EFO_0002393) now obsoleted.)

🤖 AI SummaryBased on 7 publications

Quick Overview

Human cancer cell line with metabolic and genetic characteristics.

Detailed Summary

YAPC is a human cancer cell line derived from pancreatic ductal adenocarcinoma (PDAC). It is characterized by distinct metabolic subtypes, including glycolytic and lipogenic profiles, which influence its response to metabolic inhibitors. The cell line exhibits variations in glucose and glutamine utilization, impacting its sensitivity to targeted therapies. YAPC is used in research to study metabolic reprogramming in cancer and to evaluate the efficacy of drugs targeting metabolic pathways. Its genetic and metabolic features make it a valuable model for understanding tumor heterogeneity and developing personalized treatment strategies.
Generated on 6/17/2025

Basic Information

Database IDCVCL_1794
SpeciesHomo sapiens (Human)
Tissue SourceAscites[UBERON:UBERON_0007795]

Donor Information

Age43
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseasePancreatic carcinoma
LineagePancreas
SubtypePancreatic Adenocarcinoma
OncoTree CodePAAD

DepMap Information

Source TypeDSMZ
Source IDACH-000332_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.His179Arg (c.536A>G)Unspecified-PubMed=35297208
MutationSimpleKRASp.Gly12Val (c.35G>T)HeterozygousAcquiredUnknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,12
D13S317
8,12
D16S539
9
D18S51
17
D19S433
13
D21S11
31,31.2
D2S1338
18,24
D3S1358
17
D5S818
11,13
D7S820
9,11
D8S1179
13,15
FGA
21,22
Penta D
10,13
Penta E
5,19.4
TH01
7,9
TPOX
8
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Growth dependency of a new human pancreatic cancer cell line, YAPC, on autocrine interleukin-1alpha stimulation.

Yamada T., Okajima F., Adachi M., Ohwada S., Kondo Y.

Int. J. Cancer 76:141-147(1998).

Web Resources